ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: L07 • ACR Convergence 2022

    Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study

    Di Wu1, Jing Li1, Dong Xu1, Li Wang1, Jianmin Fang2, Dan Ross3 and Fengchun Zhang4, 1Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, 2Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, 3RemeGen Co., San Diego, CA, 4Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China

    Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
  • Abstract Number: L13 • ACR Convergence 2022

    Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block

    Stephanie Benjamin1, Lisa Vi2, Diptendu Chatterjee1, Edgar Jaeggi1, Marie Wahren-Herlenius3, Amelia Ruffatti4, Linda Hiraki5, Michelle Lohbihler2, Lusia Sepiashvili1, Carl Laskin6, Meena Fatah1, Daniela Dominguez5, Lawrence Ng5, Anthony Gramolini2, Vincent Christoffels7, Stephanie Protze2 and Robert Hamilton8, 1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Universitå di Padova, Padova, Italy, 5The Hospital for Sick Children, Toronto, ON, Canada, 6Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, 7Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, 8Hospital for Sick Children, Markham, ON, Canada

    Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
  • Abstract Number: 0082 • ACR Convergence 2022

    Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients

    Jean Park, W. Cliff Rutter, Will Cavers, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI

    Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) are considered at risk for serious COVID infections due to their…
  • Abstract Number: 0221 • ACR Convergence 2022

    Identifying and Addressing Gaps in Systemic Lupus Erythematosus Care via Multimodal Continuing Medical Education

    Katie Robinson1, Jillian Scavone1, William Cioffi1, Robert Esgro1 and Leonard Calabrese2, 1Vindico Medical Education, Thorofare, NJ, 2Cleveland Clinic, Cleveland, OH

    Background/Purpose: Given the recent advances in the management of patients systemic lupus erythematosus (SLE), rheumatology and primary care providers are challenged to administer the latest…
  • Abstract Number: 0334 • ACR Convergence 2022

    Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records

    Zara Izadi1, Alfredo Aguirre2, Christine Anastasiou2, Julia Kay3, Gabriela Schmajuk4 and Jinoos Yazdany5, 1University of California San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3UCSF, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5UCSF, San Rafael, CA

    Background/Purpose: Real-world data could provide valuable information in the study of lupus nephritis (LN), if these cases could be reliably identified. A lack of ability…
  • Abstract Number: 0351 • ACR Convergence 2022

    The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study

    Yasuhiro Hasegawa1, Yoshiyuki Arinuma2, Yu Matsueda1, Kenji Oku3 and Kunihiro Yamaoka4, 1Kitasato University School of Medicine, Sagamihara, Japan, 2Kitasato University, Kanagawa, Japan, 3Kitasato University, Chigasaki, Japan, 4Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan

    Background/Purpose: Low disease activity (LDA) and remission in patients with systemic lupus erythematosus (SLE) can reduce organ damage accrual and improve prognosis. We investigated the…
  • Abstract Number: 0517 • ACR Convergence 2022

    Cortical Surface Area Correlates with Cognitive Efficiency and Disease Measures in Childhood-Onset Systemic Lupus Erythematosus

    Santiago Arciniegas1, Sarah Mossad2, Tala El Tal3, Victoria Lishak4, Stephanie Fevrier5, Ibrahim Mohamed6, Joanna Law2, Lawrence Ng2, Paris Moaf2, Helen Branson2, Adrienne Davis2, Linda Hiraki7, Deborah Levy8, ashley Danguecan2, George Ibrahim5 and Andrea Knight3, 1University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 4The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, 5The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, 6The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, ON, Canada 3Institute of Biomedical Engineering, University of Toronto, Brampton, ON, Canada, 7The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, 8Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Cognitive difficulties are common in children with childhood-onset SLE (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase understanding of…
  • Abstract Number: 0638 • ACR Convergence 2022

    Identification of New Candidate Drugs for SLE Using a Drug Repurposing Transcriptomic Approach on Blood, Skin and Kidney Samples from 3439 Patients

    Maxime DUBOIS1, Renaud FELTEN1 and jacques-eric gottenberg2, 1Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 2Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Despite improvements in the understanding of the pathogenesis of Systemic Lupus Erythematosus (SLE), very few new treatments have proven their effectiveness. Drug development is…
  • Abstract Number: 0658 • ACR Convergence 2022

    Integrative Analysis of Cell-Specific Human Endogenous Retrovirus Expression and Host Gene Expression Identifies Associations with Clinical SLE Phenotypes

    Zachary Cutts1, Sarah Patterson2, Lenka Maliskova1, Chun Ye2, Maria Dall'Era3, Jinoos Yazdany4, Lindsey Criswell5, Charles Langelier6, Marina Sirota7 and Cristina M Lanata8, 1University of California, San Francisco, San Francisco, 2University of California, San Francisco, San Francisco, CA, 3University of California, Division of Rheumatology, San Francisco, CA, 4UCSF, San Francisco, CA, 5National Human Genome Research Institute, NIH, Bethesda, MD, 6UCSF, San Francisco, 7UCSF, SF, 8NIH/NHGRI, Washington, DC

    Background/Purpose: Human endogenous retroviruses (HERVs) and long interspersed nuclear elements (LINEs) make up 5-8% and 21% of the human genome, respectively. Their expression may contribute…
  • Abstract Number: 0746 • ACR Convergence 2022

    Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial

    Ho SO1, Evelyn Chow2, Isaac Cheng1, Xerox Lau2, Tena Li1, Cheuk Chun Szeto2 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit…
  • Abstract Number: 0962 • ACR Convergence 2022

    Variability in Racial Disparities in Pregnancy Outcomes in Women with SLE by Diagnosis Algorithm

    Megan Clowse1, Jim Oates2, Katie Kirchoff2, April Barnado3, Saira Sheikh4, Leslie Crofford3 and Amanda Eudy5, 1Duke University, Durham, NC, 2Medical University of South Carolina, Charleston, SC, 3Vanderbilt University Medical Center, Nashville, TN, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5Duke University, Raleigh, NC

    Background/Purpose: Disparities in pregnancy outcomes among women with SLE remain understudied, with few available racially-diverse datasets. We previously validated algorithms to identify pregnancies in women…
  • Abstract Number: 0983 • ACR Convergence 2022

    Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Jake Altier, Fedelis Mutiso, Paul Nietert, Sheldon Litwin and Jim Oates, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Initially used as an antimalarial, hydroxychloroquine (HCQ) is standard of care treatment for systemic lupus erythematosus (SLE) and is used as monotherapy or adjunct…
  • Abstract Number: 1000 • ACR Convergence 2022

    Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study

    J. Michelle Kahlenberg1, Iñaki Sanz2, Chun Wu3, Sarah Hu3, Jin Hyang Kim3, Shalabh Singhal3 and Ian M. Catlett3, 1University of Michigan, Ann Arbor, MI, 2Emory University, Atlanta, GA, 3Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines (eg, Type 1 IFNs, IL-23, and IL-12) involved in lupus pathogenesis. Deucravacitinib (DEUC) has a…
  • Abstract Number: 1192 • ACR Convergence 2022

    Celiac Disease in Patients with Systemic Lupus Erythematosus: An Analysis of Nationwide Inpatient Sample

    Jiayi Zheng1, Ruoning Ni2, Guangchen Zou3, Yuhao Zeng4, Naeem ijaz1 and Yani Zhang5, 1The Wright Center for Graduate Medical Education, Scranton, PA, 2Ascension Saint Agnes Hospital, Iowa City, IA, 3Danbury Hospital, Danbury, CT, 4Cleveland Clinic Akron General, Akron, OH, 5MedStar Union Memorial Hospital, Baltimore, MD

    Background/Purpose: Celiac disease is an autoimmune disease characterized by the immunologic reaction to gluten by lymphocytes. Although recent studies suggest an association between celiac disease…
  • Abstract Number: 1365 • ACR Convergence 2022

    Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database

    Ivone Kim, Debra Ryan, Carmen Cheng and Cindy Kortepeter, Food and Drug Administration, Silver Spring, MD

    Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…
  • 1
  • 2
  • 3
  • …
  • 88
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences